Relmada Advances Two Key Drug Candidates | Business and Finance News

Relmada Therapeutics is on a fast track with two breakthrough drug candidates: NDV-01, showing 95% complete response rates in early trials for bladder cancer—with 76% sustaining it for a full year—and sepranolone, poised to treat Prader-Willi Syndrome after finalizing its delivery system. Both are set for IND filings by year-end, backed by a newly strengthened leadership team and $217M in cash to fund operations through 2029. Manufacturing scaling for NDV-01 is the top priority, with the company confident in hitting all milestones as it gears up for pivotal Phase Three trials. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2e8c181a15c1fc78